Trials / Terminated
TerminatedNCT04070313
A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- TTY Biopharm · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To verify the efficacy of S-1 adjuvant chemotherapy in resectable pancreatic cancer. * Primary Endpoint: Relapse-free survival (RFS) * Secondary Endpoints: 2-year survival rate, 2-year relapse-free survival (RFS) rate, safety profile
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | S-1 | Eligible patients will receive S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 28 in a 6-week cycle. |
Timeline
- Start date
- 2019-07-11
- Primary completion
- 2021-10-31
- Completion
- 2021-10-31
- First posted
- 2019-08-28
- Last updated
- 2021-12-06
Locations
4 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT04070313. Inclusion in this directory is not an endorsement.